Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a report issued on Friday, Marketbeat.com reports.

Several other brokerages also recently commented on KZR. Wells Fargo & Company reduced their target price on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, December 19th. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Trading Down 3.1 %

Shares of KZR stock opened at $5.71 on Friday. The stock has a 50-day simple moving average of $6.33 and a 200 day simple moving average of $6.73. Kezar Life Sciences has a fifty-two week low of $5.20 and a fifty-two week high of $11.35. The stock has a market capitalization of $41.66 million, a P/E ratio of -0.43 and a beta of 0.19. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On Kezar Life Sciences

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in Kezar Life Sciences by 613.8% in the 4th quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after acquiring an additional 10,219 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Kezar Life Sciences in the 4th quarter worth about $217,000. BML Capital Management LLC purchased a new stake in Kezar Life Sciences in the 4th quarter worth about $327,000. XTX Topco Ltd lifted its stake in Kezar Life Sciences by 256.1% in the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after acquiring an additional 37,504 shares in the last quarter. Finally, Shay Capital LLC purchased a new stake in Kezar Life Sciences in the 4th quarter worth about $398,000. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.